tiprankstipranks
Pieris Pharmaceuticals (PIRS)
NASDAQ:PIRS

Pieris Pharmaceuticals Stock Price & Analysis

530 Followers

PIRS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.14 - $5.79
Previous Close$1.14
Volume140.92K
Average Volume (3M)191.41K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$66.83M
Total Debt (Recent Filing)$13.25M
P/E Ratio-1.9
Beta0.48
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.58
Shares Outstanding74,406,253
R-Squared0.07
Standard Deviation0.20
10 Day Avg. Volume128,015
30 Day Avg. Volume191,414
P/B Ratio1.91
P/S Ratio3.04
P/CF Ratio46.20
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha-0.01
Number of Analyst Covering0


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

PIRS FAQ

What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was $1.14 and its highest was $5.79 in the past 12 months.
    What is Pieris Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Pieris Pharmaceuticals’s upcoming earnings report date?
    Pieris Pharmaceuticals’s upcoming earnings report date is Nov 09, 2022 which is in 42 days.
      How were Pieris Pharmaceuticals’s earnings last quarter?
      Pieris Pharmaceuticals released its earnings results on Aug 04, 2022. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.03.
        Is Pieris Pharmaceuticals overvalued?
        According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pieris Pharmaceuticals pay dividends?
          Pieris Pharmaceuticals does not currently pay dividends.
          What is Pieris Pharmaceuticals’s EPS estimate?
          Pieris Pharmaceuticals’s EPS estimate is -$0.16.
            How many shares outstanding does Pieris Pharmaceuticals have?
            Pieris Pharmaceuticals has 74,406,250 shares outstanding.
              What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
              Pieris Pharmaceuticals reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -5.495%.
                Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
                Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at 2M.

                  ---

                  Pieris Pharmaceuticals Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  5
                  The Pieris Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Pieris Pharmaceuticals

                  Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis